Podcasts about cancer care

This week we bring together urologists and radiologists to work towards a shared goal of innovating on kidney cancer care. Dr. Jason Abel, Professor of Urology and Radiology at the University of Wisconsin, and Dr. Louis Hinshaw, Section Chief of Abdominal Imaging Intervention at the University of Wisconsin, join our host Dr. Ruchika Talwar for a multidisciplinary conversation regarding the treatment of renal tumors. --- SYNPOSIS Their discussion covers the history and benefits of collaboration between urology and interventional radiology (IR), advances in image-guided procedural technologies, and the importance of teamwork in improving patient outcomes. The episode also considers the encouraging, but limited data in IR treatments such as microwave ablation and discusses the lasting role for surgery. Finally, Dr. Abel and Dr. Hinshaw share their experiences in establishing a successful interdisciplinary kidney cancer program. Ultimately, they conclude that the future of renal tumor treatment lies not in silos, but in collaboration. --- TIMESTAMPS 00:00 - Introduction 04:04 - Collaboration Between Urologists and Interventional Radiologists 05:58 - Advancements in Ablation 10:05 - Patient Selection 15:19 - Technical Considerations 26:57 - Post-Ablation Surveillance and Recurrence Management 33:19 - Conclusion

How should BC improve its rural cancer care? Guest: Cyndi Logan, Myeloma Patient from Quesnel Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of 'Speak the Truth,' listeners are invited to register for the upcoming ABC Call to Council conference. Mike is joined with Justin Greene and Mary Young, both cancer survivors, discuss their newly launched Cancer Care Ministry at Salem Heights Church. They share their personal journeys with cancer, the unique challenges faced by cancer patients, and how the new ministry aims to provide practical support, emotional comfort, and spiritual guidance. Key topics include the importance of humor, sharing stories, and maintaining hope amid suffering. Additionally, they emphasize the necessity for other churches to consider establishing similar support groups and provide resources for starting such initiatives. 00:00 Introduction and Conference Announcement01:39 Welcome to Speak the Truth Podcast02:13 Introducing Justin Green and Mary Young02:37 Justin's Cancer Journey04:48 Mary's Cancer Journey06:15 Launching the Cancer Care Ministry16:33 The Oasis Cancer Support Groups27:39 Encouragement and Resources for Churches30:17 Conclusion and Contact InformationEpisode MentionsOur Journey of Hope - Cancer Resources 

Raising awareness about disparities in cancers impacting women, screening among Indigenous populations, and barriers to accessing care is essential. The Association of Cancer Care Centers (ACCC) is dedicating to providing up-to-date information on approaches to improving women's health screening, education, and prevention in Indigenous subpopulations. In this episode, CANCER BUZZ speaks with Tricia Numan, MD, assistant professor of pathology at Roswell Park Comprehensive Cancer Center about geographical challenges to accessing care and strategies for culturally tailored approaches for indigenous women.    “[There] are some major things that have happened in not so recent past to native populations, and I think it's really important for health care providers to take that recent history into account when they're caring for native patients.” – Tricia Numan, MD   “If you want to culturally tailor your health care I think that it's very important, because it's not a one size fits all.”   Tricia Numan, MD Gynecologic Pathologist Assistant Professor of Pathology Department of Pathology & Laboratory Medicine Department of Indigenous Cancer Health Roswell Park Comprehensive Cancer Center Buffalo, New York Resources:  Roswell Park Department of Indigenous Cancer Health Oncology Issues Roswell Park Article  

From initial symptoms to survivorship, understanding bone cancer care is crucial for primary care providers. During this episode of Banner Health's Making the Rounds podcast, we'll explore the complexities of bone cancer diagnoses, treatment pathways and the vital role of primary care providers in supporting patients across every stage of their journey. We'll cover the different types of bone cancer, the importance of a multidisciplinary approach and how primary care can bridge the gap between oncology specialists and families facing this difficult diagnosis.You'll hear from Dr. Ahmed Elabd, an orthopedic oncology specialist at Banner - University Medicine Tucson and the University of Arizona Cancer Center, and assistant professor of orthopedics at the University of Arizona College of Medicine - Tucson. Dr. Elabd is a specialist in treating both pediatric and adult patients with bone cancer.

On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new companion podcast to further shine a spotlight on the issues shaping the future of modern oncology. TRANSCRIPT Dr. Nathan Pennell: Hello, I'm Dr. Nate Pennell, welcoming you to the first episode of our new podcast, ASCO Education: By the Book. The podcast will feature engaging discussions between editors and authors from the ASCO Educational Book. Each month, you'll hear nuanced views on key topics in oncology featured in Education Sessions at ASCO meetings, as well as some deep dives on the advances shaping modern oncology. Although I am honored to serve as the editor-in-chief (EIC) of the ASCO Educational Book, in my day job, I am the co-director of the Cleveland Clinic Lung Cancer Program and vice chair for clinical research for the Taussig Cancer Center here in Cleveland. I'm delighted to kick off our new podcast with a discussion featuring the Ed Book's previous editor-in-chief. Dr. Don Dizon is a professor of medicine and surgery at Brown University and works as a medical oncologist specializing in breast and pelvic malignancies at Lifespan Cancer Institute in Rhode Island. Dr. Dizon also serves as the vice chair for membership and accrual at the SWOG Cancer Research Network. Don, it's great to have you here for our first episode of ASCO Education: By the Book. Dr. Don Dizon: Really nice to be here and to see you again, my friend. Dr. Nathan Pennell: This was the first thing I thought of when we were kicking off a podcast that I thought we would set the stage for our hopefully many, many listeners to learn a little bit about what the Ed Book used to be like, how it has evolved over the last 14 years or so since we both started here and where it's going. You started as editor-in-chief in 2012, is that right? Dr. Don Dizon: Oh, boy. I believe that is correct, yes. I did two 5-year stints as EIC of the Educational Book, so that sounds about right. Although you're aging me very clearly on this podcast. Dr. Nathan Pennell: I had to go back in my emails to see if I could figure out when we started on this because we've been working on it for some time. Start out a little bit by telling me what do you remember about the Ed Book from back in the day when you were applying to be editor-in-chief and thinking about the Ed Book. What was it like at that time? Dr. Don Dizon: You know, it's so interesting to think about it.  Ten years ago, we were both in a very different place in our careers, and I remember when the Ed Book position came up, I had been writing a column for ASCO. I had done some editorial activities with other journals for sure, but what always struck me was it was very unclear how one was chosen to be a part of the education program at ASCO. And then it was very unclear how those faculty were then selected to write a paper for the Educational Book. And it was back in the day when the Educational Book was completely printed. So, there was this book that was cherished among American fellows in oncology. And it was one that, when I was newly attending, and certainly two or three years before the editor's position came up, it was one that I referenced all the time. So, it was a known commodity for many of us. And there was a certain sense of selectivity about who was invited to write in it. And it wasn't terribly transparent either. So, when the opportunity to apply for editor-in-chief of the Educational Book came up, I had already been doing so much work for ASCO. I had been on the planning committees and served in many roles across the organization, and editing was something I found I enjoyed in other work. So, I decided to put my name in the ring with the intention of sort of bringing the book forward, getting it indexed, for example, so that there was this credit that was more than just societal credit at ASCO. This ended up being something that was referenced and acknowledged as an important paper through PubMed indexing. And then also to provide it as a space where we could be more transparent about who was being invited and broadening the tent as to who could participate as an author in the Ed Book. Dr. Nathan Pennell: It's going to be surprising to many of our younger listeners to learn that the Educational Book used to be just this giant, almost like a brick. I mean, it was this huge tome of articles from the Education Sessions that you got when you got your meeting abstracts book at the annual meeting. And you can always see people on the plane on the way out of Chicago with their giant books. Dr. Don Dizon: Yes. Dr. Nathan Pennell: That added lots of additional weight to the plane, I'm sure, on the way out. Dr. Don Dizon: And it was not uncommon for us to be sitting at an airport, and people would be reading those books with highlighters. Dr. Nathan Pennell: I fondly remember being a fellow and coming up and the Ed Book was always really important to me, so I was excited. We'll also let the listeners in on that. I also applied to be the original editor-in-chief of the Ed Book back in 2012, although I was very junior and did not have any real editorial experience. I think I may have been section editor for The Oncologist at that point. And I had spoken to Dr. Ramaswamy Govindan at WashU who had been the previous editor-in-chief about applying and he was like, “Oh yeah. You should absolutely try that out.” And then when Dr. Dizon was chosen, I was like, “Oh, well. I guess I didn't get it.” And then out of the blue I got a call asking me to join as the associate editor, which I was really always very thankful for that opportunity. Dr. Don Dizon: Well, it was a highly fruitful collaboration, I think, between you and I when we first started. I do remember taking on the reins and sort of saying, “You know, this is our vision of what we want to do.” But then just working with the authors, which we did, about how to construct their papers and what we were looking for, all of that is something I look back really fondly on. Dr. Nathan Pennell: I think it was interesting too because neither one of us had really a lot of transparency into how things worked when we started. We kind of made it up a little bit as we went along. We wanted to get all of the faculty, or at least as many of them as possible contributing to these. And we would go to the ASCO Education Committee meeting and kind of talk about the Ed Book, and we were thinking about, you know, how could we get people to submit. So, at the time it wasn't PubMed indexed. Most people, I think, submitted individual manuscripts just from their talk, which could be anywhere from full length review articles to very brief manuscripts. Dr. Don Dizon: Sometimes it was their slides with like a couple of comments on it. Dr. Nathan Pennell: And some of them were almost like a summary of the talk. Yeah, exactly. And so sort of making that a little more uniform. There was originally an honorarium attached, which went away, but I think PubMed indexing was probably the biggest incentive for people to join. I remember that was one of the first things you really wanted to get. Dr. Don Dizon Yeah. And, you know, it was fortuitous. I'd like to take all the credit for it, but ASCO was very forward thinking with Dr. Ramaswamy and the conversations about going to PubMed with this had preceded my coming in. We knew what we needed to do to get this acknowledged, which was really strengthening the peer review so that these papers could meet the bar to get on PubMed. But you know, within the first, what, two or three years, Nate, of us doing this, we were able to get this accepted. And now it is. If you look at what PubMed did for us, it not only increased the potential of who was going to access it, but for, I think the oncology community, it allowed people access to papers by key opinion leaders that was not blocked by a paywall. And I thought that was just super important at the time. Social media was something, but it wasn't what it is now. But anybody could access these manuscripts and it's still the case today. Dr. Nathan Pennell: I think it's hard to overstate how important that was. People don't realize this, but the Ed Book is really widely accessed, especially outside the US as well. And a lot of people who can't attend the meeting to get the print, well, the once print, book could actually get access to essentially the education session from the annual meeting without having to fly all the way to the US to attend. Now, you know, we have much better virtual meeting offerings now and whatnot. But at the time it was pretty revolutionary to be able to do that. Dr. Don Dizon: Yeah, and you know, it's so interesting when I think back to, you know, this sort of evolution to a fully online publication of the Ed Book. It was really some requests from international participants of the annual meeting who really wanted to continue to see this in print. At that time, it was important to recognize that access to information was not uniform across the world. And people really wanted that print edition, maybe not for themselves, but so that access in more rural areas or where access in the broadband networks were not established that they still could access the book. I think things have changed now. We were able, I think, in your tenure, to see it fully go online. But even I just remember that being a concern as we went forward. Dr. Nathan Pennell: Yeah, we continued with the print book that was available if people asked for it, but apparently few enough people asked for it that it moved fully online. One of the major advantages of being fully online now is of course, it does allow us to publish kind of in real time as the manuscripts come out in the months leading up to the meeting, which has been, I think, a huge boon because it can build momentum for the Education Sessions coming in. People, you know, really look forward to it. Dr. Don Dizon: Yeah, that was actually a concern, you know, when we were phasing out Ed Book and going to this continuous publication model where authors actually had the ability to sort of revise their manuscript and that would be automatically uploaded. You had a static manuscript that was fully printed, and it was no longer an accurate one. And we did have the ability to fix it. And it just goes to show exactly what you're saying. This idea that these are living papers was really an important thing that ASCO embraced quite early, I think. Dr. Nathan Pennell: And with the onset of PubMed indexing, the participation from faculty skyrocketed and almost within a couple of years was up to the vast majority of sessions and faculty participating. Now I think people really understand that this is part of the whole process. But at the time I remember writing out on my slides in all caps, “THIS IS AN EXPECTATION.” And that's about the best word I could give because I asked if we could make people do it, and they were like, no, you can't make people do it. Dr. Don Dizon: So right.  Actually, I don't think people are aware of the work on the back end every year when I was on as EIC, Nate and myself, and then subsequently Dr. Hope Rugo would have these informational sessions with the education faculty and we would tout the Ed Book, tout the expectation, tout it was PubMed indexed and tout multidisciplinary participation. So, we were not seeing four manuscripts reflecting one session. You know, this encouragement to really embrace multidisciplinary care was something that very early on we introduced and really encouraged people not to submit perspective manuscripts, but to really get them in and then harmonize the paper so that it felt like it was, you know, one voice. Dr. Nathan Pennell: I consider that after PubMed indexing, the next major change to the Ed Book, that really made it a better product and that was moving from, you know, just these short individual single author manuscripts to single session combined manuscript that had multiple perspectives and topics, really much more comprehensive review articles. And I don't even remember what the impetus was for that, but it was really a success. Dr. Don Dizon: Yeah, I mean, I think in the beginning it was more of a challenge, I think, because people were really not given guidance on what these papers were supposed to look like. So, we were seeing individual manuscripts come forward. Looking back, it really foreshadowed the importance of multidisciplinary management. But at the time, it was really more about ensuring that people were leaving the session with a singular message of what to do when you're in clinic again. And the goal was to have the manuscripts reflect that sort of consensus view of a topic that was coming in. There were certain things that people still argued would not fit in a multidisciplinary manuscript. You know, if you have someone who's writing and whose entire talk was on the pathology of thyroid cancer. Another topic was on survivorship after thyroid cancer. It was hard to sort of get those two to interact and cover what was being covered. So, we were still getting that. But you're right, at the end of my tenure and into yours, there were far fewer of those individual manuscripts. Dr. Nathan Pennell: And I think it's even made it easier to write because now, you know, you just have to write a section of a manuscript and not put together an entire review. So, it has helped with getting people on board. Dr. Don Dizon: Well, the other thing I thought was really interesting about the process is when you're invited to do an Education Session at ASCO, you're either invited as a faculty speaker or as the chair of the session. And the responsibility of the chair is to ensure that it flows well and that the talks are succinct based on what the agenda or the objectives were as defined by the education committee for that specific group. But that was it. So really being named “Chair” was sort of an honor, an honorific. It really didn't come with responsibility. So, we use the Ed Book as a way to say, “As chair of the session, it is your responsibility to ensure A, a manuscript comes to me, but B, that the content of that paper harmonizes and is accurate.” And it was very rare, but Nate, I think we got dragged into a couple of times where the accuracy of the manuscript was really called into question by the chair. And those were always very, very tricky discussions because everyone that gets invited to ASCO is a recognized leader in their field. Some of us, especially, I would probably say, dating back 10 years from today, the data behind Standards of Care were not necessarily evidence-based. So, there were a lot of opinion-based therapies. You know, maybe not so much in the medical side, but certainly some of it. But when you went to, you know, surgical treatments and maybe even radiotherapy treatments, it was really based on, “My experience at my center is this and this is why I do what I do.” But those kinds of things ended up being some of the more challenging things to handle as an editor. Dr. Nathan Pennell: And those are the– I'll use “fun” in a broad sense. You know, every once in a while, you get an article where it really does take a lot of hands-on work from the editor to work with the author to try to revise it and make it a suitable academic manuscript. But you know what? I can't think, at least in recent years, of any manuscripts that we turned down. They just sometimes needed a little TLC. Dr. Don Dizon: Yeah. And I think the other important thing it reminds me of is how great it was that I wasn't doing this by myself. Because it was so great to be able to reach out to you and say, “Can you give me your take on this paper?” Or, “Can you help me just join a conference call with the authors to make sure that we're on the same page?” And then on the rare example where we were going to reject a paper, it was really important that we, as the editorial team, and I include our ASCO shepherder, through the whole process. We had to all agree that this was not salvageable. Fortunately, it happened very rarely. But I've got to say, not doing this job alone was one of the more important facets of being the EIC of ASCO's Educational Book. Dr. Nathan Pennell: Well, it's nice to hear you say that. I definitely felt that this was a partnership, you know, it was a labor of love. So, I want to go to what I consider sort of the third major pillar of the changes to the Ed Book during your tenure, and that was the introduction of a whole new kind of manuscript. So up to, I don't know, maybe seven or eight years ago, all the articles were authored just by people who were presenting at the Annual Meeting. And then you had an idea to introduce invited manuscripts. So take me through that. Dr. Don Dizon: Yeah, well, you know, again, it went to this sort of, what can people who are being asked to sort of lead ASCO for that year, what can they demonstrate as sort of a more tangible contribution to the Society and to oncology in general? And I think that was the impetus to use the Ed Book for everyone who was in a leadership position to make their mark. That said, I was here, and I was either president of the society or I was Education Program Chair or Scientific Program Chair, and they got to select an article type that was not being covered in the annual meeting and suggest the authors and work with those authors to construct a manuscript. Never did any one of those folks suggest themselves, which I thought was fascinating. They didn't say, “I want to be the one to write this piece,” because this was never meant to be a presidential speech or a commemorative speech or opportunity for them as leaders. But we wanted to ensure that whatever passion they had within oncology was represented in the book. And again, it was this sort of sense of, I want everyone to look at the Ed Book and see themselves in it and see what they contributed. And that was really important for those who were really shepherding each Annual Meeting each year for ASCO that they had the opportunity to do that. And I was really pleased that leadership really took to that idea and were very excited about bringing ideas and also author groups into the Educational Book who would not have had the opportunity otherwise. I thought that was just really nice. It was about inclusiveness and just making sure that people had the opportunity to say, “If you want to participate, we want you to participate.” Dr. Nathan Pennell: Yeah, I agree. I think the ASCO leadership jumped on this and continues to still really appreciate the opportunity to be able to kind of invite someone on a topic that's meaningful to them. I think we've tried to work in things that incorporate the presidential theme each year in our invited manuscript, so it really allows them to put kind of a stamp on the flavor of each edition. And the numbers reflect that these tend to be among our more highly read articles as well. Dr. Don Dizon: You know, looking back on what we did together, that was something I'm really, really quite proud of, that we were able to sort of help the Educational Book evolve that way. Dr. Nathan Pennell: I agree. You brought up briefly a few minutes ago about social media and its role over time. I think when we started in 2012, I had just joined Twitter now X in 2011, and I think we were both sort of early adopters in the social media. Do you feel like social media has had a role in the growth of the Ed Book or is this something that you think we can develop further? Dr. Don Dizon: When we were doing Ed Book together, professional social media was actually a quite identified space. You know, we were all on the same platform. We analyzed what the outcomes were on that platform and our communities gathered on that platform. So, it was a really good place to highlight what we were publishing, especially as we went to continuous publishing.  I don't remember if it was you or me, but we even started asking our authors for a tweet and those tweets needed work. It was you. It was you or I would actually lay in these tweets to say, “Yeah, we need to just, you know, work on this.” But I think it's harder today. There's no one preferred platform. Alternate platforms are still evolving. So, I think there are opportunities there. The question is: Is that opportunity meaningful enough for the Ed Book to demonstrate its return on an investment, for example? What I always thought about social media, and it's still true today, is that it will get eyes on whatever you're looking at far beyond who you intended to see it. So, you know, your tweets regarding a phase 3 clinical trial in lung cancer, which were so informative, were reaching me, who was not a lung oncologist who doesn't even see lung cancer and getting me more interested in finding that article and more and more pointing to the Educational Book content that speaks to that piece, you know. And I think coupling an impression of the data, associating that with something that is freely accessed is, I think, a golden opportunity not only for our colleagues, but also for anyone who's interested in a topic. Whether you are diagnosed with that cancer or you are taking care of someone with that cancer, or you heard about that cancer, there are people who would like to see information that is relevant and embedded and delivered by people who know what they're talking about. And I think our voices on social media are important because of it. And I think that's where the contribution is. So, if we had to see what the metric was for any social media efforts, it has to be more of the click rates, not just by ASCO members, but the click rates across societies and across countries. Dr. Nathan Pennell: Yeah, social media is, I mean, obviously evolving quite a bit in the last couple of years. But I do know that in terms the alt metrics for the track access through social media and online, the ones that are shared online by the authors, by the Ed Book team, do seem to get more attention. I think a lot of people don't like to just sit with a print journal anymore or an email table of contents for specific journals. People find these articles that are meaningful to them through their network and oftentimes that is online on social media. Dr. Don Dizon: Yes, 100%. And you know what I think we should encourage people to do is look at the source. And if the Ed Book becomes a source of information, I think that will be a plus to the conversations in our world. We're still dealing with a place where, depending on who sponsored the trial, whether it was an industry-sponsored trial, whether it was NCI sponsored or sponsored by the National Institutes of Health, for example, access to the primary data sets may or may not be available across the world, but the Ed Book is. And if the Ed Book can summarize that data and use terms and words that are accessible no matter what your grade level of education is. If we can explain the graphs and the figures in a way that people can actually easily more understand it. If there's a way that we structure our conversations in the Ed Book so that the plethora of inclusion/exclusion criteria are summarized and simplified, then I think we can achieve a place where good information becomes more accessible, and we can point to a summary of the source data in places where the source is not available. Dr. Nathan Pennell: One of the other things that I continue to be surprised at how popular these podcasts are. And that gives you an opportunity pretty much the opposite. Instead of sort of a nugget that directs you to the source material, you've got a more in-depth discussion of the manuscript. And so, I'm delighted that we have our own podcast. For many years, the Ed Book would sort of do a sort of a “Weird Al takeover” of the ASCO Daily News Podcast for a couple of episodes around the Annual Meeting, and I think those were always really popular enough that we were able to argue that we deserved our own podcast. And I'm really looking forward to having these in-depth discussions with authors. Dr. Don Dizon: It's an amazing evolution of where the Ed Book has gone, right? We took it from print only, societally only, to something that is now accessed worldwide via PubMed. We took it from book to fully online print. And now I think making the content live is a natural next step. So, I applaud you for doing the podcast and giving people an opportunity actually to discuss what their article discusses. And if there's a controversial point, giving them the freedom and the opportunity to sort of give more nuanced views on what may not be something that there's 100% consensus over. Dr. Nathan Pennell: Yes. Well, I hope other people enjoy these as well. Just want to highlight a few of the things that have happened just in the couple years since you stepped down as editor-in-chief. One of them, and I don't know if you noticed, but last year we started adding manuscripts from the ASCO thematic meetings, so ASCO GI and ASCO GU, something we had certainly talked about in the past, but had lacked bandwidth to really do. And they seem to be pretty widely accessed. Dr. Don Dizon: That's fantastic. Yes, I do remember talking about the coverage of the thematic meetings and you're right, this takes a long time to sort of concentrate on the Annual Meeting. It may seem like everything happens in the span of like eight weeks. Dr. Nathan Pennell: It does feel like that sometimes. Dr. Don Dizon: Right? But this is actually something that starts a year before, once the education program is set. We're in the room when they set it. But then it's really chasing down manuscripts and then making sure that they're peer reviewed because the peer review is still really important, and then making sure that any revisions are made before it's finalized and goes to press. That is a many months process. So, when we're trying to introduce, “Oh, we should also do ASCO GU or-,” the question was, how do you want to do that given this very, very involved process going forward? So, I'm glad you were able to figure it out. Dr. Nathan Pennell: Well, it's challenging. I don't think people realize quite the compressed timeline for these. You know, the Education Session and authors and invited faculty are picked in the fall, and then basically you have to start turning in your manuscripts in February, March of the following year. And so, it's a really tight turnaround for this. When we talk about the ASCO thematic meetings, it's an even tighter window. Dr. Don Dizon: Right, exactly. Dr. Nathan Pennell: And so, it's challenging to get that moving, but I was really, really proud that we were able to pull that off. Dr. Don Dizon: Well, congratulations again. And I think that is a necessary step, because so much of what's going on in the various disease management sites is only covered cursorily through the Annual Meeting itself. I mean, there's just so much science breaking at any one time that I think if we want to comprehensively catalog the Year in Review in oncology, it kind of behooves us to do that. Dr. Nathan Pennell: Some other things that are coming up because we now have manuscripts that are going to be coming in year-round, and just to kind of make it easier on the editorial staff, we're going to be forming an editorial board. And in addition to our pool of reviewers who get ASCO points, please feel free to go online to the ASCO volunteer portal and sign up if you are interested in participating. So, moving forward, I'm really excited to see where things are going to go. Dr. Don Dizon: Well, that's great. That's great. And I do remember talking about whether or not we needed to have an editorial board. At least when I was there, having this carried by three people was always better than having it carried by one person. And I think as you expand the potential for submissions, it will be very helpful to have that input for sure. And then it gives another opportunity for more members to get involved in ASCO as well. Dr. Nathan Pennell: Absolutely. People want involvement, and so happy to provide that. Dr. Don Dizon: Yes. Dr. Nathan Pennell: Is there anything we didn't cover that you would like to mention before we wrap up? Dr. Don Dizon: Well, I will say this, that ASCO and through its publications not only has had this real emphasis on multidisciplinary management of cancers, especially where it was relevant, but it also always had a stand to ensure representation was front and center and who wrote for us. And I think every president, every chair that I've worked with naturally embraced that idea of representation. And I think it has been a distinct honor to say that during my tenure as EIC, we have always had a plethora of voices, of authors from different countries, of genders, that have participated in the construction of those books. And it stands as a testament that we are a global community and we will always be one. Dr. Nathan Pennell: Well, thank you for that. And I'm happy to continue that as we move forward. Well, Don, thank you. It's been great speaking with you. You played such a pivotal role in the Ed Book's evolution and I'm so glad you were able to join me for our inaugural episode. Dr. Don Dizon: Well, I'm just tickled that you asked me to be your first guest. Thank you so much, Nate. Dr. Nathan Pennell: And I also want to thank our listeners for joining us today. We hope you'll join us again for more insightful views on topics you'll be hearing at the Education Sessions from ASCO meetings throughout the year, as well as our periodic deep dives on advances that are shaping modern oncology. Have a great day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Nathan Pennell  @n8pennell @n8pennell.bsky.social   Dr. Don Dizon @drdondizon.bsky.social  Follow ASCO on social media:   @ASCO on X (formerly Twitter)   ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Nathan Pennell:      Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron     Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi  Dr. Don Dizon: Stock and Other Ownership Interests: Midi, Doximity Honoraria: UpToDate, American Cancer Society Consulting or Advisory Role: AstraZeneca, Clovis Oncology, Kronos Bio, Immunogen Research Funding (Institution): Bristol-Myers Squibb          

What if a medical specialty society could drive groundbreaking research, fuel a global movement, and train the next generation of clinical investigators—all while tripling its membership in just five years? In a world of rapidly evolving cancer care, how can associations champion new modalities and build a community around transformative treatment approaches? In this episode of Associations Thrive, host Joanna Pineda interviews Jena Stack, Executive Director of the Society of Interventional Oncology (SIO). Jena discusses:How interventional oncology is emerging as the fourth pillar of cancer care, alongside surgery, chemotherapy, and radiation.How interventional oncologists use minimally invasive, image-guided techniques to target cancer with fewer side effects and faster recovery.How SIO has tripled in membership since 2020, growing from a small niche society to nearly 1,500 members globally.SIO's impressive governance model, which prioritizes relationship-building and alignment between the board and staff.How SIO is leading its own multi-million dollar clinical trials to address gaps in evidence and influence standards of care. Typically, this role has been reserved for pharma companies or academic institutions.The creation of the Clinical Trial Collaborative (CTC), a new research community and certificate program that trains and connects principal investigators.SIO's long-term vision to empower more physicians to lead studies and expand access to minimally invasive cancer treatments.The importance of "pausing to retreat" during growth, and how SIO balances ambition with sustainability.References:SIO Website

In this inspiring episode, I sit down with Rachel Frankenthal, a board-certified Physician Assistant and Menopause Society Certified Practitioner, whose work is transforming the lives of cancer survivors. Rachel specialises in gynaecological oncology at UCLA, supporting women through both cancer treatment and survivorship—particularly those navigating treatment-induced menopause.But Rachel's story is anything but ordinary! From her early days as a Broadway performer to becoming a leading voice in survivorship care, she shares how her journey shaped her passion for holistic, patient-centred healthcare. She has played a pivotal role in developing UCLA's Gynaecologic Cancer Survivorship Program and started a dedicated menopause clinic to support survivors in reclaiming their well-being.Join us as we discuss the power of integrative care, movement, and mindfulness, and how Rachel is changing the future of menopause support for cancer survivors. This conversation is full of wisdom, hope, and a reminder that the right care can change lives.Episode Highlights:00:00 Intro05:27 Rachel's Yoga Journey13:07 Comprehensive Patient Follow-Up Visits16:51 Post-Treatment Confusion and Anxiety20:15 Embracing a Healthcare Paradigm Shift23:13 Menopausal Symptoms in Cancer Survivors24:30 "Advocating Awareness in Cancer Care"29:09 Empowering Mid-Level Providers in Oncology31:42 Yoga Program Reduces Treatment Side Effects35:35 Community Healing Through Connection38:17 Normalising Post-Cancer Intimacy ChallengesFind Rachel here https://www.instagram.com/rachelfrankenthal/ Attached are resources: The British Gyn Cancer Society Guidelines https://thebms.org.uk/publications/bms-guidelines/management-of-menopausal-symptoms-following-treatment-of-gynaecological-cancer/- Here's the link to Rachel's course "Hormone Therapy for Gyn Cancer Survivors": https://heatherhirschacademy.com/course/managing-hormone-therapy-for-gynecologic-cancer-survivors/Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, is joined by Dr. Lisa Harlan-Williams, associate director for education at the cancer center, to discuss the variety of careers involved in the field of cancer care and research, beyond doctors and nurses. Dr. Harlan-Williams shares her own career path and talks about various initiatives at KU Cancer Center to attract and train for the oncology workforce. They highlight the importance of early exposure to different career opportunities and the educational programs available, including shadowing professionals and summer research internships. The discussion also touches on the growing demand for cancer care professionals due to increasing cancer cases and workforce shortages. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about educational opportunities and programs for students considering a career in cancer research at KU Cancer Center Learn about the Accelerate Cancer Education summer research program at KU Cancer Center Read about the C-CLEAR summer internship program at KU Cancer Center Learn more about the Jewell Summer Research Training Program at KU Cancer Center    

In this episode, we dive into the transformative power of art therapy in cancer care. Art therapy goes beyond traditional treatment by offering patients a creative outlet to express their emotions, manage stress, and find relaxation during their journey. Emphasizing the process over perfection, art therapy creates a safe, supportive space for individuals to explore their creativity and enhance their emotional well-being. Whether through painting, drawing, or other forms of expression, patients are encouraged to engage in art as a tool for healing and connection.About Our Guest:We are joined by Lisa Shea, MA, ATR-BC. Lisa holds a Bachelor of Fine Arts from Miami University and a Master's in Art Therapy from Wright State University. With a diverse background in psychiatric hospitals, community mental health centers, and schools, Lisa has made a profound impact on her patients' lives. In 2012, she became the first full-time art therapist at the Cleveland Clinic's Taussig Cancer Center, where she's played a crucial role in bringing the healing power of art to cancer patients.Tune in to hear how art therapy is reshaping the patient experience and offering a new path to emotional wellness during the challenging journey of cancer care.

Karla Mans Giroux delves into the research on radical remission and how lifestyle choices can help overcome cancer. Discover powerful strategies and stories of hope that highlight the impact of holistic living on cancer recovery. #RadicalRemission #LifestyleChoices #CancerRecovery

Join Dr. Henning Saupe as he explores non-toxic, gentle methods to treat cancer effectively. Learn about alternative therapies that support healing without the harsh side effects of traditional treatments. Discover a holistic approach to cancer care. #NonToxicTreatment #CancerHealing #HolisticHealth

CancerNetwork® visited Sibley Memorial Hospital of Johns Hopkins Medicine to speak with a variety of experts about therapeutic advancements and ongoing research initiatives across several different cancer fields. As part of each discussion, clinicians highlighted how collaboration across different departments has positively impacted treatment planning, decision-making, and outcomes at their institution. These experts included the following: ·      Rachit Kumar, MD, an assistant professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins School of Medicine and a radiation oncologist specializing in genitourinary and gastrointestinal cancers at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center for Sibley Memorial Hospital and Suburban Hospital; ·      Michael J. Pishvaian, MD, PhD, director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs, and associate professor of Oncology at Johns Hopkins School of Medicine; ·      Nina Wagner-Johnston, MD, a professor of Oncology and the director of Lymphoma Drug Development at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, director of Hematologic Malignancies National Capital Region, and co-director of Clinical Research for Hematologic Malignancies; ·      Valerie Lee, MD, an assistant professor of Oncology at Johns Hopkins University School of Medicine and a medical oncologist at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital; ·      Armine Smith, MD, the director of urologic oncology at the Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, and an assistant clinical professor of Urology at the Brady Urological Institute of Johns Hopkins University School of Medicine; ·      Pouneh Razavi, MD, the director for Breast Imaging in the National Capital Region and an instructor in Radiology and Radiological Science; ·      and Curtiland Deville Jr., MD, medical director of the Johns Hopkins Proton Therapy Center and clinical director of Radiation Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital. Altogether, their insights demonstrated how multidisciplinary teamwork has improved outcomes ranging from patient survival to healthcare resource utilization across a wide range of diseases including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and others.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.

Burnout among oncologists is a serious concern, and artificial intelligence (AI) represents a potential solution, says Debra Patt, MD, PhD, MBA, a practicing oncologist and breast cancer specialist in Austin, Texas, who also serves as the chair of the AI task force for the American Society of Clinical Oncology. Technological advances are poised to improve cancer care while reducing the documentation burden for oncologists, she tells Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles, and Steven Spielberg Family Chair in Hematology-Oncology. Dr. Patt describes the various practical ways in which AI is already changing oncology clinics, but acknowledges a generational divide that will need to be bridged: “I would say that the youngest generation of oncologists that is coming out, they are digital natives. They have grown up with this,” she explains. But for those who have been in practice longer, “Change management for us looks a little bit different than it does for the younger generation of oncologists that just sort of do this naturally.” Dr. Patt reported no relevant financial disclosures. Dr. Figlin reported various financial relationships.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.

“We are obsessed with patient experience and outcomes. EBITDA is just a byproduct.”This philosophy has guided MOC Cancer Care and Research Centre to profitable growth while delivering exceptional chemotherapy care through 24 community cancer centers. Founded by four medical oncologists, MOC began with a vision to bridge the massive gap between expensive private hospitals and overcrowded government facilities. Today, MOC is India's largest network of purpose-built centers that focus exclusively on delivering standardized, high-quality cancer care closer to patients' homes.MOC's model built on the two cornerstones of enhancing the cancer patient's journey and improving the medical oncologist's experience has proven remarkably successful. What's even more impressive is their roster of 48 medical oncologists with zero attrition - unheard of in an industry where doctor mobility is the norm.In this conversation with Mayank Khanduja (Partner, Elevation Capital), co-founders Dr Vashisht Maniar, Dr Ashish Joshi and COO Manish Jobanputra discuss their journey of creating a standardized, patient-centric cancer care delivery system.In this episode, you will gain insights on:> Identifying the structural inefficiencies in India's cancer care system> Scaling standardized care across multiple centers> Creating a dual focus on patient journey and caregiver experience> Building doctor satisfaction through autonomy and support> Achieving growth through patient outcomes

Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

In today's episode, Dr. Mitchell Posner, Dr. Sarah Shubeck, and Dr. Jelani Williams on the University of Chicago Medicine's new Comprehensive Cancer Center. Scheduled to open in 2027, the new center is a seven-floor, 575,000-square-foot building planned to have 80 private beds and 90 consultation and outpatient rooms. At the moment, the center is anticipated to see 200,000 outpatient visits and 5000 inpatient admissions annually. This would be the city of Chicago's first freestanding cancer pavilion.How will we ensure that this new center prioritizes the community's needs? In Chicago's South Side, cancer death rates are twice the national average, and cancer is also the second-leading cause of death on the South Side behind heart disease. In this conversation, you'll hear about the center's development, what patients can expect, and most importantly, the Department of Surgery's commitment to ensure the cancer center supports those who are most vulnerable. Dr. Mitchell Posner is the Thomas D. Jones Distinguished Service Professor of Surgery, Chief of the Section of General Surgery, and the Chief Clinical Officer of the University of Chicago Medicine Comprehensive Cancer Center. From clinical trials for cancer treatment to his more than 250 articles, abstracts, and book chapters, Dr. Posner is a leading authority in the management of upper gastrointestinal cancers. He is frequently voted among the country's best doctors. He is the past president of the Society of Surgical Oncology. He is deputy editor of the Annals of Surgical Oncology and section editor for the gastrointestinal cancer section of the journal Cancer. He served as chairman of the Gastrointestinal Committee of the American College of Surgeons Oncology Group (ACOSOG).Dr. Sarah Shubeck is an Assistant Professor in the Department of General Surgery. She is a Breast Surgical oncologist specializing in breast surgery, cancer, and benign disease treatment. In addition to her clinical practice, Dr. Shubeck's research has been published in many journals including Cancer, JAMA Surgery, and Annals of Surgical Oncology.Dr. Jelani Williams is a 5th-year general surgery resident at the University of Chicago. He is an aspiring surgical oncologist and attended the Eastern Virginia Medical School. He has published research on predictive models and surgery for metastatic pancreatic neuroendocrine tumors as well as the use of machine learning to distinguish benign and malignant thyroid nodules amongst other topics. Deep Cuts: Exploring Equity in Surgery comes to you from the Department of Surgery at the University of Chicago, which is located on Ojibwe, Odawa and Potawatomi land.Our executive producer is Tony Liu. Our senior producers are Alia Abiad, Caroline Montag, and Chuka Onuh. Our production team includes Megan Teramoto, Ria Sood, Ishaan Kumar, and Daniel Correa Bucio. Our senior editor and production coordinator is Nihar Rama. Our editorial team also includes Beryl Zhou and Julianna Kenny-Serrano. The intro song you hear at the beginning of our show is “Love, Money Part 2” from Chicago's own Sen Morimoto off of Sooper Records. Our cover art is from Leia Chen.A special thanks this week to Dr. Jeffrey Matthews — for his leadership, vision, and commitment to caring for the most vulnerable in our communities. Let us know — what have you most enjoyed about our podcast. Where do you see room for improvement? You can reach out to us on Instagram @deepcutssurgery. Find out more about our work at deepcuts.surgery.uchicago.edu.

Investing in Bizarro World Episodes: https://youtube.com/playlist?list=PLIAfIjKxr02sAztzlJNy1ug5bDvTVZkME&si=w2d_EF-B5jMo1dYD Subscribe to Investing In Bizarro World: @bizarroworld Programming Note: April is going to be a busy month at Digest Publishing. This week, we'll debut new research about the lucrative investments associated with making vital medicines in the low-gravity environment of space. Later this month, Gerardo will have a new gold recommendation in the April issue of Junior Resource Monthly. If you don't want to miss it, become a member of Junior Resource Monthly today. Details here: https://bit.ly/423kYo9The free version of the 310th episode of Investing in Bizarro World is now published.Here's what was covered:Macro Musings - Nick's morning routine. Gold hits new highs. So does copper. Silver next? Precious metal price targets. Market Takes - A bear market with no recession. Inflation update. Bizarro Banter - Politicians use immigration as a tool for votes. Amelia's Story: MedImpact denies 3-year-old's critical cancer medicine. Premium Portfolio Picks - For paid listeners only. Subscribe here: https://bit.ly/4j7VeNv0:00 Introduction0:46 Macro Musings: Nick's Morning Routine. Record Gold (again). Copper Tariffs. Silver Shining.17:33 Market Takes: Tariffs Drive Prices Higher. Growth & Inflation Seesaw26:12 Bizarro Banter: MedImpact Denies Child's Cancer Care. Immigration as Political Football. Read the article: https://www.wmar2news.com/matterformallory/family-faces-new-battle-as-pharmacy-benefit-manager-denies-3-year-olds-cancer-medication40:21 Premium Portfolio Picks: You need to subscribe to Bizarro World Live to get this section: https://bit.ly/4j7VeNvLast year, Gerardo went and toured a new American copper mine with our own John Carl. The stock is moving now as domestic copper stocks catch a bid. See the info from our tour here: https://bit.ly/41TN4CbPLEASE NOTE: There are now two versions of this podcast. 1. Bizarro World Live — Pay $2 per episode to watch us record the podcast live every Thursday and get Premium Portfolio Picks every week. You can do that here: https://bit.ly/4j7VeNv2. Bizarro World Free — Published the Monday after the live recording with no Premium Portfolio Picks.Visit our website Daily Profit Cycle for more content like this and more! https://dailyprofitcycle.com/

This week on the show, Petrendologist Charlotte Reed talks with Dr. Noah Synder-Mackler, an associate professor at Arizona State University's School of Life Sciences, about dogs needing friends and Brian Morvant, the Program Manager for CancerCare's Pet Assistance & Wellness (PAW) Program, about helping Cancer Patients stay together with their pets.

In this episode of Dear Cancer, I'm Beautiful, we discuss an often-overlooked aspect of cancer care: oral health. Onco-Radioligist Dr. Abida Taher and Pediatric Dentist Dr. Robyn Lesser, the experts behind (un) cancer, join the show to explain why oral care is so important during cancer treatment, how to protect your teeth and gums, and their unique products designed to help maintain oral health. We explore the impact of chemotherapy, radiation, and immunotherapy on oral health, covering common issues like mouth sores, dry mouth, infections, and long-term dental complications. Dr. Taher and Dr. Lesser also discuss why oral health is frequently overlooked in cancer treatment and why that needs to change. They share their unique approach to preventive dental care and the science behind the products they have developed for cancer patients. Tune in for valuable information and practical tips on maintaining your smile, before, during and after cancer treatment!

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, hosts Dr. Marc Hoffmann, associate professor specializing in Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center and medical director of the lymphoma program at KU Cancer Center, where he also serves as medical director for quality improvement initiatives. Beyond his clinical expertise, Dr. Hoffmann has contributed significantly to research in lymphoma and chronic lymphocytic leukemia (CLL), and he actively participates in national cooperative group clinical trials. Dr. Hoffmann shares his career path into the field of oncology, innovations in lymphoma and CLL treatments, as well as the unique aspects of KU Cancer Center's lymphoma program. The conversation also covers Dr. Hoffmann's Peace Corps experience in West Africa, his involvement in clinical trials, and advice for medical students interested in hematology and oncology. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the lymphoma program at KU Cancer Center Learn about chronic lymphocytic leukemia (CLL) Learn more about CAR T-cell therapy at KU Cancer Center Learn more about Dr. Marc Hoffmann Watch a video of Dr. Hoffmann explaining how blood cancer is diagnosed  

Since 2009, CancerCare and the Triple Negative Breast Cancer Foundation have partnered to provide vital support to those affected by TNBC. In this episode of Cancer Out Loud, host Cassie Spector (oncology social worker and CancerCare's Breast and Gynecological Cancer Program Coordinator) speaks with Allison McNeill, a Triple Negative Breast Cancer (TNBC) Day ambassador, about her experience with TNBC. They discuss the challenges of diagnosis, treatment, and survivorship and the importance of support systems and community. Allison shares her experiences navigating family dynamics, communicating with her children, and balancing work and health during treatment. The conversation emphasizes the need for advocacy, awareness, and the emotional complexities of living with TNBC . Episode Takeaways:- Trust what the doctors are saying.- Don't Google things; trust the process.- It's okay to let go of control a little bit.- Stay active, get outside, and connect with nature.- Don't react until there's something to react to.- You have to meet this new version of yourself.- Just say yes to help when it's offered.- Knowledge is power in this area.- It's okay to push back and ask questions.

In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. Duncan Lascelles, a distinguished professor at North Carolina State University and a leading expert in veterinary pain management and surgery. Dr. Lascelles explores the complex relationship between pain and cancer in veterinary patients, highlighting how both cancer and its treatments can cause significant discomfort—and how pain itself may even influence cancer progression. Together, they dive into findings from clinical and laboratory studies and share best practices for pain assessment and management. Dr. Lascelles also emphasizes the importance of early intervention, client education, and the profound impact of effective pain control on patient outcomes and quality of life. Tune in to gain a deeper understanding of how thoughtful pain management can shape the future of veterinary oncology.

In this episode, Dr. Nasha Winters shares her powerful journey with cancer and the urgent need for a paradigm shift in oncology. She explores the limitations of the current cancer care model, the critical role of mitochondria in chronic illness, and why asking different questions is essential for improving patient outcomes. Dr. Winters also introduces MTOMICS, a cutting-edge data platform designed to revolutionize cancer treatment by integrating personalized, data-driven insights. Listen to the full episode to learn more:  The standard cancer care model has seen little progress in outcomes since 1971. Cancer is affecting younger populations, signaling the need for new approaches. Mitochondrial health is a cornerstone of cancer and chronic disease management. Integrative medicine offers evidence-based strategies to enhance patient care. Community and collaboration are essential for driving meaningful change. Data-driven, decentralized healthcare models can empower both patients and practitioners. And much more! Tune in to discover how integrative oncology, cutting-edge research, and patient empowerment are reshaping the future of cancer care.

We are delighted to partner with Western Radiation Oncology today, with two of their distinguished radiation oncologists joining us on the Prostate Health Podcast.  LDR (Low Dose Rate) prostate brachytherapy has recently been an underutilized treatment for prostate cancer. However, advancements in modern techniques have demonstrated that LDR brachytherapy, a procedure that can be performed quite easily in an ambulatory surgery center, offers high cure rates with minimal long-term complications, making it a convenient, non-invasive option for men with prostate cancer. Today, we chat with Dr. Steven Kurtzman and Dr. Ankit Agarwal, two distinguished radiation oncologists working to expand access to LDR brachytherapy by partnering with urologists to establish new programs across the United States.  Drs. Kurtzman and Agarwal are national leaders in targeted real-time intraoperative planned brachytherapy. With over 7,000 implants performed in the past two decades and more than 700 procedures conducted annually, they have managed to preserve this specialized technique despite its limited expansion in recent years. Based primarily in the Bay Area, California, they provide exceptional cancer care while collaborating with urologists, medical oncologists, and prostate cancer specialists across the United States to assist in establishing LDR programs in ambulatory surgery centers nationwide to provide high-quality prostate cancer care. Tune in to learn more about this promising treatment option! Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: Who are the most viable candidates for LDR brachytherapy? How the treatments for low, intermediate, and high-risk prostate cancer patients differ The benefits of a combination of brachytherapy and external beam radiation for high-risk prostate cancer patients How factors like urinary function, bowel function, and prostate size can influence men's eligibility for LDR brachytherapy Why prostate size is no longer a limitation for brachytherapy treatment How is the LDR brachytherapy procedure performed? What can patients expect in terms of recovery and side effects following brachytherapy? Post-therapy safety precautions Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Sponsor Links:  Western Radiation Oncology Brachytherapy for Prostate Cancer with Dr. Steven Kurtzman and Dr. Ankit Agarwal on YouTube Expanding Treatment Options at Ambulatory Surgical Centers: LDR Brachytherapy for Prostate Cancer    

For many cancer patients, the journey to treatment can be just as challenging as the treatment itself. What if that journey could be shortened—by bringing care directly to their homes?In this episode of the podcast, we're joined by Jennifer Hunsey, BSN, RN, Nursing Program Coordinator at Mayo Clinic Florida, to explore the innovative Cancer Care Beyond Walls initiative. This groundbreaking program is bringing oncology treatments directly to patients, minimizing barriers to care, and reducing the burden of travel. Jennifer discusses how the Mayo Clinic uses technology and a patient-centered approach to deliver chemotherapy and supportive care in the comfort of patients' homes.We learn the inspiration behind this initiative, the role of virtual oversight and home health nursing, as well as the challenges faced and the patient experiences that have shaped the program. Jennifer also shares exciting insights into future expansion plans that could reshape how cancer care is delivered.This episode offers a powerful look at the future of oncology care—listen now to discover the Cancer Care Beyond Walls program's impact on patients and the importance of expanding care beyond traditional settings.Jennifer Hunze, BSN, RN, the RN Program Coordinator for Mayo Clinic's Cancer Care Beyond Walls program. With over 20 years of nursing experience—17 of those in oncology—Jen has worked in various roles, including inpatient hematology, infusion nursing, and cancer treatment management. She now leads efforts to develop innovative cancer care delivery models aimed at improving access and the overall patient experience.

Join hosts Heather, Lauren, and John as they sit down with Dr. Sengar, an accomplished oncologist from Alabama Cancer Care, a network committed to delivering quality cancer care to underserved communities. In this episode, we explore the unique challenges of accessing cancer care in rural areas, despite the higher incidence of the disease. We also dive into the rising trend of cancer diagnoses among younger populations and discuss innovations in the future of cancer treatment. Tune in now!

In a recent episode of Oncology on the Go, several oncologists discussed the impact of the COVID-19 pandemic on oncology care, 5 years later. Each doctor discussed a different aspect of multidisciplinary care, including medical oncology, radiation oncology, and epidemiology. CancerNetwork® spoke with leading clinicians including:  ·      Aditya Bardia, MD, MPH, FSCO, professor in the Department of Medicine, Division of Hematology/Oncology, and director of Translational Research Integration at the University of California Los Angeles Health Jonsson Comprehensive Cancer Center; ·      Ritu Salani, MD, director of Gynecologic Oncology at the University of California Los Angeles, and ONCOLOGY® editorial advisory board member; ·      Scarlett Lin Gomez, PhD, MPH, a professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco (UCSF), and co-leader of the Cancer Control Program at UCSF Helen Diller Family Comprehensive Cancer Center ·      Marwan F. Fakih, MD, professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope Comprehensive Cancer Center; ·      Elizabeth Zhang-Velten, MD, a radiation oncologist at Keck Medicine of University of Southern California;  ·      Frances Elain Chow, MD, neuro-oncologist at the University of Southern California (USC) Norris Comprehensive Cancer Center ·      James Yu, MD, MHS, FASTRO, assistant professor adjunct, Department of Radiation Oncology, Smilow Cancer Hospital at Saint Francis Hospital, and ONCOLOGY® editorial advisory board member.  The COVID-19 pandemic disrupted routine cancer care in a number of ways. Many patients were unable to receive timely screening, diagnosis, and treatment, Fakih noted. Additionally, Bardia stated that the pandemic led to a decrease in the number of patients participating in clinical trials. One of the most significant changes in oncology care, according to Salani, has been the increased use of telehealth. Telehealth has allowed patients to receive care from the comfort of their own homes, which has been especially beneficial for patients who live in rural areas or who have difficulty traveling. Telehealth has also made it easier for patients to connect with their doctors and to receive support from other members of their care team.  For Gomez, the COVID-19 pandemic also highlighted the importance of addressing the structural and social drivers of health. These are the conditions in which people are born, grow, live, work, and age that can affect their health. For example, people who live in poverty or who lack access to healthy food are more likely to develop cancer. The pandemic has led to a renewed focus on addressing these disparities. Overall, the COVID-19 pandemic has had a profound impact on oncology care. However, it has also led to a number of positive changes, such as the increased use of telehealth and the focus on addressing the structural and social drivers of health. In the years to come, it will be important to continue to build on these changes in order to improve the lives of patients with cancer.

Send us a textHealwell's Glossary of the Massage Therapy ProfessionNew Healwell Class: Cultural Competency for Bodyworkers and Healthcare ProvidersHealwell News 1:24State and National News 2:13Association News 8:13Events 10:58Davonna Willis InterviewBeneficial Ownership ChecklistCOMTA Likes Us!ABMP EventsAMTA Call for SpeakersMTF GrantsIMTRC RegistrationABMP NewsAMTA NewsSupport the showSend us an email: podcast@healwell.orgLeave us a voice message: 703-468-1799 Check out our interview-style podcast: InterdisciplinaryYou can support Healwell and the cool things we make by donating here!Other ways join in: Leave us a review on Apple Podcasts Check Healwell's live and online classes Continue the conversation with a free 3-day trial of the Healwell Community Find a copy of Rebecca Sturgeon's book: "Oncology Massage: An Integrative Approach to Cancer Care" Thank you to ABMP for sponsoring us!Healwell is a 501(c)(3) non-profit based out of the Washington DC area. Check us out at www.healwell.org

Send us a textJoin us for an impactful episode where we sit down with Rochelle Prosser, a powerhouse in healthcare advocacy and the founder of Orchid Healthcare Solutions. Rochelle's life changed dramatically when her family was struck by cancer, leading her to become a fierce advocate for better care. With her extensive background as a neurotrauma ICU nurse, she shares her unique insights into the challenges of navigating the healthcare system from the inside and the outside. Tune in as Rochelle recounts her touching journey, from the heart-wrenching decisions in her daughter's fight against cancer to her husband's own cancer battle. She discusses the three pivotal barriers that hinder access to quality oncology care—knowledge, access, and effective navigation of the healthcare system. Discover the vital importance of being informed and proactive in treatment decisions, the emotional complexities that accompany these journeys, and the monumental efforts needed to advocate for those you love. Through her organization, Rochelle empowers families by providing crucial resources and knowledge to help navigate their cancer journeys. Listen in to understand how her story can inspire change and make an impact on the lives of those facing similar trials. Subscribe, share, and spread the word—let's create a community of informed and empowered patients together!Thanks for tuning in to this episode of Follow The Brand! We hope you enjoyed learning about the latest marketing trends and strategies in Personal Branding, Business and Career Development, Financial Empowerment, Technology Innovation, and Executive Presence. To keep up with the latest insights and updates from us, be sure to follow us at 5starbdm.com. See you next time on Follow The Brand!

Native Americans are located throughout the United States in both urban and rural environments. In this episode of SurgOnc Today®, Drs. Michelle Huyser, Jennifer Erdrich, and Vanessa Jensen discuss challenges and unique aspects of providing Native American Cancer Care to this population from both an academic as well as community perspective.

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

In this episode of the Becker's Healthcare Podcast, host Lukas Voss explores cutting-edge advancements in gastric and esophageal cancer care with two leading experts from City of Hope. Surgical Oncologist Dr. Yanghee Woo and Medical Oncologist Dr. Dani Castillo discuss the benefits of a multidisciplinary approach, the impact of robotic-assisted minimally invasive surgery, and the latest clinical trials offering new hope for patients.This episode is sponsored by City of Hope.

In this episode of The Patient From Hell, host Samira Daswani sits down with Dr. Cara Bohon, a clinical psychologist and researcher, to explore the unique mental health challenges faced by cancer patients and survivors. They discuss the role of cognitive behavioral therapy (CBT) in cancer care, the complexities of treating cancer-related insomnia, and the shortage of mental health professionals trained in oncology.Dr. Bohon and Samira also review a PCORI-funded study led by Dr. Jun J. Mao, comparing the effectiveness of CBT-I (cognitive behavioral therapy for insomnia) versus acupuncture for cancer-related insomnia. Dr. Bohon breaks down step-by-step sleep strategies for cancer patients, offering practical tools to improve sleep, emotional well-being, and cancer-related anxiety—even for those without access to therapy.This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features this PCORI study by Jun J Mao, MD.Check out the free mental health resources mentioned in this episode from Veterans of America here.--Your Cancer GPS is here! Step-by-step breast cancer maps based on what others have gone through and what oncologists recommend.Key Highlights:Insomnia is a major issue for cancer patients and survivors alike – beyond just trouble sleeping, it exacerbates pain, fatigue, cognitive impairment, and emotional distress, making cancer treatment even more challenging.  The clinical trial covered in this episode found that cognitive behavioral therapy for insomnia (CBT-I) led to better sleep improvements compared to acupuncture, with lasting effects even after treatment ended. While acupuncture may not be as effective as CBT-I for sleep, it showed short-term benefits for managing cancer-related pain, which can still be valuable for your mental health as wellThe problem with therapy today is not just accessibility, but also the fact that many therapists aren't trained in psycho-oncology, making it difficult for cancer patients to find mental health support tailored to their unique challenges.  Techniques from CBT-I, such as sleep restriction, stimulus control, cognitive restructuring, and relaxation exercises, can significantly improve sleep quality—even for those who can't afford professional therapy.About our guest: Dr. Cara Bohon is a clinical psychologist and researcher from Stanford University with experience scaling delivery of evidence-based mental health treatments to meet the huge needs of patients across the United States. She led clinical programs and research at Equip Health, which addressed the demand for effective eating disorder treatment by providing training and virtual delivery of evidence-based eating disorder treatment across the country and is passionate about expanding her work in oncology in the future.Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

TAL Hospitals presents a special interview on Women's Mental Health & Cancer Care with Dr. Sravani Reddy G., Founder & CEO of SOPRAV Healthcare Consulting. Hosted by Suhasini, this discussion explores the psychological impact of cancer, the role of mental well-being in recovery, and holistic healthcare solutions. Tune in on March 4th to TALRadio English on Spotify & Apple Podcast!Host : SuhasiniGuest : Dr.Sravani Reddy G.You Can Reach Dr.Sravani @soprav.com/#TALRadioEnglish #TALHospitals #WomensHealth #MentalHealthMatters #CancerCare #HolisticHealing #HealthcareLeadership #MindBodyWellness #OncologySupport #EmpowerHer #ResilientWomen #HealthEquity #WellnessJourney #TouchALife #TALRadio

A greater sense of control, feeling in partnership with their care team, and not finding reporting symptoms burdensome are just a few of the outcomes reported by people with advanced cancer in a study of an electronic intervention where they … How does reporting symptoms impact cancer care for patients? Elizabeth Tracey reports Read More »

Physician executive Shamar Young discusses his article, "Geographic disparities in advanced cancer care: a call for innovation," highlighting the uneven access to emerging cancer treatments across different health care systems. Shamar explores the impact of geography on advanced therapies like theragnostics and transarterial radioembolization (TARE), emphasizing how disparities in expertise, technology, and resources limit patient options. He discusses how specialized third-party services, such as TeleDaaS, can bridge these gaps by centralizing expertise and improving care accessibility. The conversation examines potential solutions for ensuring that all patients receive optimal cancer treatment, regardless of their location. Listeners will gain insights into how innovation in care delivery can reduce health disparities and improve patient outcomes. Our presenting sponsor is DAX Copilot by Microsoft. DAX Copilot, by Microsoft, is your AI assistant for automated clinical documentation and workflows. DAX Copilot allows physicians to do more with less and turn their words into a powerful productivity tool. DAX Copilot automates clinical documentation—making it available in the EHR within minutes—and clinical workflows, including referral letters, after-visit summaries, style and formatting customizations, and more. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Discover AI-powered solutions for clinical documentation and workflows. Click here to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

Send us a textMLB Hall of Famer Mike Schmidt called into talk about his serious battle with skin cancer (Stage 3 Melanoma) and a new initiative from CancerCare, "Your Cancer Game Plan."  It was also a thrill to talk to Mike about baseball memories of him always destroying my Cubs and his thoughts on whether the Cubs can repeat.(From 9-20-17)

Join Dr. Henning Saupe as he explores non-toxic, gentle methods to treat cancer effectively. Learn about alternative therapies that support healing without the harsh side effects of traditional treatments. Discover a holistic approach to cancer care. #NonToxicTreatment #CancerHealing #HolisticHealth

In this episode, I continue the "Your Voice. Your Health" series with a powerful conversation about step therapy, healthcare disparities, and patient advocacy. I had the privilege of speaking with Jamil Rivers, a metastatic breast cancer thriver, nationally recognized advocate, and founder of The Chrysalis Initiative. We discuss Jamil's experience from her breast cancer diagnosis to her groundbreaking work in educating healthcare providers through her Cancer Curriculum, which is transforming cancer care and addressing inequities in treatment access. We explore the flaws in the healthcare system that step therapy exposes, and discuss trustworthy resources and tactics that can empower patients to advocate for themselves and seek the care they deserve. Listen now to be inspired by Jamil's story and gain important insights into improving cancer care for all. Special thanks to Amgen for making this episode possible.

In this episode of the Precision Medicine Podcast, host Karan Cushman engages in a thought-provoking discussion with two pioneers in AI-driven oncology: Dr. Douglas Flora and Dr. Sanjay Juneja. Together, they explore how AI is revolutionizing cancer care, from earlier detection and faster diagnoses to personalized treatments and clinical trial optimization.AI's potential in oncology is game-changing. Dr. Flora and Dr. Juneja break down how AI is helping to identify cancer at its earliest, most treatable stages, automate biomarker testing, and streamline clinical trials to match patients with the best therapies faster than ever before. AI is not just a futuristic concept—it is already helping oncologists reduce misdiagnoses, improve screening accuracy, and speed up treatment approvals, all of which could significantly improve patient outcomes.But if AI is so transformative, why isn't it more widely used? Adoption remains one of the biggest hurdles, with challenges ranging from regulatory barriers and insurance limitations to the slow integration of AI into clinical practice. Karan challenges her guests to explain what needs to change for AI-driven precision medicine to reach more patients—sooner rather than later.With her patient-first perspective, Karan ensures the conversation stays focused on what these advancements mean for real people. Looking ahead to 2030, the discussion explores what a fully AI-integrated oncology system could look like—and why the revolution in cancer care isn't coming—it's already here.Dr. Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, and Dr. Sanjay Juneja is a hematologist-oncologist, social media educator, and VP of Clinical AI Operations at Tempus AI. Both guests are co-founders of Tensor Black, an education and consulting company specializing in AI applications in oncology.

In this episode of the Friends of NPACE Podcast we are joined by Molly Kisiel, nurse practitioner and director of clinical content for ACCC. We have a practical and open conversation on why oncology clinical learning is critical for primary care providers. Join NPACE and ACCC March 12-13th for a special 2-day Oncology Virtual Conference to learn more on these crucial topics! Tune in every other Wednesday for new episodes of the Friends of NPACE Podcast on your favorite streaming platform (Spotify, Apple Music, YouTube, and Amazon Music).

Bladder cancer remains a prevalent disease with significant disparities in care, particularly in underserved populations. To address this, ACCC launched a national quality improvement initiative in three phases: 1. assessment and preparation, 2. action plan implementation, and 3. monitoring for continuous improvement. Dr. Samuel Washington, from the University of California, San Francisco, discussed the initiative's early findings, highlighting site-specific approaches.   Sustainability was a key consideration, ensuring a balance between short-term wins and long-term impact. Action plans need to be both ambitious and practical to drive meaningful change. Continuing outcome monitoring will refine strategies, and the initiative could serve as a replication model in other clinical settings and cancer types. An important opportunity exists to expand multidisciplinary collaboration to include patient advocates and ensure the long-term integration of these improvements. Despite varied site objectives, all participants were committed to improving cancer care. This initiative highlights the power of structured, collaborative efforts to address disparities and enhance patient outcomes.   "Now we have an opportunity to bring in patients and advocates… and expand this type of work in a structured way to other cancers and other institutions, other sites in an already national program." – Dr. Samuel Washington   “The feasibility of the program overall was important, the fact that we could engage leadership champions at the clinic level and then multi-disciplinary team buy-in at each institution with this goal across oncology, urology, practices, radiation oncology, nursing, to all come together for each of these visits to help develop an action plan, it is something that I have not seen much of in recent years." – Dr. Samuel Washington   Samuel L. Washington III, MD, MAS  Assistant Professor of Urology,   Goldberg-Benioff Endowed Professorship in Cancer Biology  University of California, San Francisco  San Francisco, CA    Additional Resources: Implementing Shared Decision-Making in Bladder Cancer Care eCourse (https://courses.accc-cancer.org/products/implementing-shared-decision-making-in-bladder-cancer-care?_gl=1*1l9u2ab*_ga*MTU3NjkxMTU5Mi4xNzM2MTc4MTQy*_ga_HW05FVSTWC*MTczODk0Mjk3OS41MC4xLjE3Mzg5NDMyOTAuNTUuMC4w#tab-product_tab_overview) Understanding and Mitigating Disparities in Bladder Cancer (https://www.accc-cancer.org/docs/projects/bladder-cancer/understanding-and-mitigating-disparities-in-bladder-cancer-care.pdf?sfvrsn=a2630102_2&) Providing Equitable Care for Patients With Bladder Cancer (https://www.accc-cancer.org/docs/projects/bladder-cancer/accc_bladdercancer_8-5x11_patientexperienceresorce_interactive.pdf?sfvrsn=934efb33_2&) Effective Practices in Bladder Cancer Care: Multispecialty Clinics (https://www.accc-cancer.org/docs/projects/bladder-cancer/accc_bladdercancer_1_multispecialtyclinics.pdf?sfvrsn=e4cf453f_2&)

Send us a textSuicide hotline: call or text 988International Suicide HotlinesRegister for the Community Processing Event on February 25thCorey Rivera and Cal Cates address the alarming suicide rates among massage therapists by exploring underlying risk factors, including perfectionism, isolation, and occupational stress. By recognizing these nuances, the conversation encourages community engagement and accountability to promote better mental health outcomes.• Discussing general risk factors for suicide • Understanding perfectionism and its types • Examining isolation within the massage therapy profession • Highlighting the economic instability faced by massage therapists • Analyzing the impact of ACEs on mental health • Exploring job demand and control dynamics • Reflecting on the effects of COVID-19 on the workforce • Emphasizing the need for community and support in the professionHealwell Blog; Worst. Game. Ever.CDC Article: Suicide Rates by Industry and OccupationHealwell Class: Empowering Individuals to Navigate CrisisIntegrated Motivational Volitional Model of Suicidal BehaviorSupport the showSend us an email: podcast@healwell.orgLeave us a voice message: 703-468-1799 Check out our interview-style podcast: InterdisciplinaryYou can support Healwell and the cool things we make by donating here!Other ways join in: Leave us a review on Apple Podcasts Check Healwell's live and online classes Continue the conversation with a free 3-day trial of the Healwell Community Find a copy of Rebecca Sturgeon's book: "Oncology Massage: An Integrative Approach to Cancer Care" Thank you to ABMP for sponsoring us!Healwell is a 501(c)(3) non-profit based out of the Washington DC area. Check us out at www.healwell.org

In this episode, Scott Becker speaks with Pete Govorchin, President of City of Hope Chicago. They discuss City of Hope's pioneering oncology care, the integration with Cancer Treatment Centers of America, and the organization's commitment to local and national cancer patients. Pete also highlights exciting advancements in oncology, the Illinois Cancer Patient Bill of Rights, and his journey as a lifelong learner and leader in healthcare.

This episode of Integrative Cancer Solutions features an insightful conversation between Dr. Karlfeldt and Dr. Marlene Siegel, a veterinarian with nearly 40 years of experience. Dr. Siegel shares her journey from traditional allopathic medicine to a more holistic, bio-regulatory approach in veterinary care. She emphasizes the importance of identifying root causes rather than just treating symptoms, focusing on three key areas: toxicities, deficiencies, and mitochondrial dysfunction. Dr. Siegel discusses her unique approach to treating cancer in animals, explaining that cancer cells are essentially rogue cells that have lost normal communication within a toxic environment. She stresses the need to address both the body's environment and the cancer directly, highlighting the importance of proper nutrition, detoxification, and supporting the body's innate healing processes. Dr. Siegel also shares a compelling case study of Bentley, a dog with squamous cell carcinoma, demonstrating the effectiveness of her holistic treatment methods. Throughout the conversation, Dr. Siegel emphasizes the crucial role of pet parents in their animals' health. She discusses her online course, "Transforming Vet Medicine," which educates pet owners on the six steps to healing. These steps include eliminating pollutants, ensuring essential nutrients, healing the gut, detoxifying, repairing mitochondria, and addressing trapped emotions. Dr. Siegel concludes by encouraging pet owners to view health challenges as opportunities for growth and to take an active role in their pets' well-being through informed decision-making and lifestyle changes.Dr. Marlene Siegel transitioned from allopathic veterinary medicine to a holistic, bio-regulatory approach after a life-changing experience with her horse.The core of Dr. Siegel's treatment philosophy focuses on addressing toxicities, deficiencies, and mitochondrial dysfunction in animals.Dr. Siegel views cancer as rogue cells that have lost normal communication, emphasizing the need to create a healthier environment for the body to heal.A case study of Bentley, a dog with squamous cell carcinoma, demonstrates the effectiveness of Dr. Siegel's holistic treatment methods.Dr. Siegel offers an online course called "Transforming Vet Medicine" to educate pet parents on six crucial steps for healing their animals.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Hey friends! On this episode of #TheIntegrativeHealthPodcast, I had the privilege of speaking with Dr. Michael Karlfeldt, an integrative medicine specialist who's redefining cancer care. Inspired by his father's journey with colon cancer, Dr. Karlfeldt dives into how a holistic approach can empower patients and improve outcomes.We talked about:Why inflammation is a key driver in cancer development and how to address it.Cutting-edge therapies like photodynamic therapy and their potential to target cancer cells effectively.The importance of holistic care, including physical, emotional, and spiritual health.If you or someone you know is navigating a cancer diagnosis, this episode is packed with insights and hope. Dr. Karlfeldt's story is a testament to the power of integrative care.Dr. Michael Karlfeldt, ND, PhD, is an integrative medicine expert passionate about redefining cancer care. After losing his father to colon cancer, Dr. Karlfeldt dedicated his career to exploring holistic solutions. He focuses on treating inflammation, empowering patients, and utilizing advanced therapies like photodynamic therapy to achieve better outcomes. His approach is rooted in addressing the whole person—physically, emotionally, and spiritually.Facebook: https://www.facebook.com/michael.karlfeldtInstagram: https://www.instagram.com/thekarlfeldtcenter Website: https://www.facebook.com/michael.karlfeldtPODCAST Thank you for listening please subscribe and share! - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Shop supplements: https://healthybydrjen.shop/ CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavorites WATCH THIS:https://www.youtube.com/watch?v=2lSyAFy5U4U&list=PLaDiqj0yz1eeCOATXPoUDt8HEJxz1_lfW - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FOLLOW ME: Instagram :: https://www.instagram.com/integrativedrmom/ Facebook :: https://www.facebook.com/pflegmed Tik Tok :: https://www.tiktok.com/@integrativedrjen YouTube :: https://www.youtube.com/@integrativedrmom - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you). I truly appreciate your support of my channel. Thank you for watching! Video is not spons...

Does personalized precision medicine have the potential to treat chronic and life-threatening diseases like cancer and enhance longevity? In this episode, we connect with Dr. John Oertle, the Chief Medical Director at Envita Medical Centers, to dive into the innovative field of personalized precision medicine – something that has played a critical role in helping many late-stage cancer patients recover holistically… Dr. Oertle specializes in chronic infectious disease, immunotherapy, and precision oncology. He leads the molecular tumor board for Envita Medical Centers and does research and development in the fields of oncology and infectious disease. Dr. Oertle and his team treat diseases by identifying and addressing the root causative factors, considering the detailed genetics, epigenetics, pharmacogenomics, environmental, and other factors that contribute to patient recovery. Want to learn how this level of in-depth analysis can help build a customized treatment protocol for each individual patient? What does it mean to go beyond the standard one-size-fits-all protocols? Join the conversation now to find out! Hit play to discover: Why focusing on outcomes is so critical to effectively treating chronic diseases. The benefits of providing individualized cancer therapy. How to teach the immune system to attack harmful tumors. The role that biological age plays in disease prevention and recovery. Click here to follow along with Dr. Oertle and his important work at Envita Medical Centers! Boost Your Brainpower with 15% OFF!  Fuel your mind with BrainSupreme Supplements and unlock your full potential. Get 15% OFF your order now using this exclusive link: brainsupreme.co/discount/findinggenius Hurry—your brain deserves the best! Episode also available on Apple Podcasts: http://apple.co/30PvU9C